2 biotech stocks plummet more than 25% after the FDA rejects their drug applications - Business Insider

  • 📰 BusinessInsider
  • ⏱ Reading Time:
  • 20 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 11%
  • Publisher: 51%

Indonesia Berita Berita

Indonesia Berita Terbaru,Indonesia Berita utama

2 biotech stocks plummet more than 25% after the FDA rejects their drug applications

for its hemophilia A gene therapy valoctocogene roxaparvovec. The FDA is requesting more data on the durability of the drug candidate with its primary endpoint being annualized bleeding rate.

The expected timeline of when BioMarin will have the data the FDA is requesting in its CRL will be in late 2021 or early 2022, based on when the last patient will complete the two-year follow-up to its ongoing phase 3 study.Markets InsiderSomething is loading.By clicking ‘Sign up’, you agree to receive marketing emails from Business Insider as well as other partner offers and accept our

 

Terima kasih atas komentar Anda. Komentar Anda akan dipublikasikan setelah ditinjau.

Do You Want To create 3d Amazing Video Intro Logo Animation Video In $5 ? Contact Me : LogoAnimation MadeOnFiverr Top Logo Animation Best Logo Animation

Berita ini telah kami rangkum agar Anda dapat membacanya dengan cepat. Jika Anda tertarik dengan beritanya, Anda dapat membaca teks lengkapnya di sini. Baca lebih lajut:

 /  🏆 729. in İD

Indonesia Berita Terbaru, Indonesia Berita utama

Similar News:Anda juga dapat membaca berita serupa dengan ini yang kami kumpulkan dari sumber berita lain.

Inside the French Riviera's pandemic party problem - Business InsiderBusiness Insider is a fast-growing business site with deep financial, media, tech, and other industry verticals. Launched in 2007, the site is now the largest business news site on the web. Houston we have a problem.... or in this case, France. 25 guys and only one woman, huge problem.
Sumber: BusinessInsider - 🏆 729. / 51 Baca lebih lajut »

Stock market news today: Stocks mixed after S&P 500 record close - Business InsiderBusiness Insider is a fast-growing business site with deep financial, media, tech, and other industry verticals. Launched in 2007, the site is now the largest business news site on the web.
Sumber: BusinessInsider - 🏆 729. / 51 Baca lebih lajut »

Maersk Q2 earnings: World's biggest shipping firm's profits rise 25% - Business InsiderBusiness Insider is a fast-growing business site with deep financial, media, tech, and other industry verticals. Launched in 2007, the site is now the largest business news site on the web.
Sumber: BusinessInsider - 🏆 729. / 51 Baca lebih lajut »

Stocks to buy, 5 companies set for gains as the economy reopens - Business InsiderBusiness Insider is a fast-growing business site with deep financial, media, tech, and other industry verticals. Launched in 2007, the site is now the largest business news site on the web.
Sumber: BusinessInsider - 🏆 729. / 51 Baca lebih lajut »

Stock picks to buy, 7 back-to-school firms for big returns: Jefferies - Business InsiderBusiness Insider is a fast-growing business site with deep financial, media, tech, and other industry verticals. Launched in 2007, the site is now the largest business news site on the web.
Sumber: BusinessInsider - 🏆 729. / 51 Baca lebih lajut »

US stocks will outperform their global peers, driven by tech, says JPM - Business InsiderBusiness Insider is a fast-growing business site with deep financial, media, tech, and other industry verticals. Launched in 2007, the site is now the largest business news site on the web.
Sumber: BusinessInsider - 🏆 729. / 51 Baca lebih lajut »